Searchable abstracts of presentations at key conferences in endocrinology

ea0042p4 | (1) | Androgens2016

Expression of a novel androgen-regulated long noncoding RNA correlates with progression-free survival in prostate cancer patients

Kohvakka Annika , Kivinummi Kati , Kytola Ville , Ylipaa Antti , Annala Matti , Urbanucci Alfonso , Nykter Matti , Visakorpi Tapio

Prostate cancer (PC) is the second most frequently diagnosed cancer in men worldwide. 10–20% of the PC patients develop castration-resistant prostate cancer (CRPC) that has no curative therapies. There are also no effective prognostic markers to predict emergence of CRPCs. Long noncoding RNAs (lncRNAs) are a recently found group of RNAs that are not translated into proteins. Many of them are found to be differentially expressed in cancer, and shown to have a regulative ro...

ea0042p38 | (1) | Androgens2016

Histological modeling of prostate cancer

Ruusuvuori Pekka , Valkonen Mira , Kartasalo Kimmo , Visakorpi Tapio , Latonen Leena , Nykter Matti

Prostate cancer is multifocal in nature, and histological grading is the key clinical prognostic factor. To build non-subjective histological analysis tools, and to model the multifocality of prostate cancer within the organ, we use analysis of histological images to quantitatively describe prostate cancer. Our current effort shows how heterogeneity in prostate tissue due to cancer or spatial location can be quantified with image-derived features. We use high-resolution digita...

ea0042p17 | (1) | Androgens2016

Next generation sequencing panels to predict response to hormonal therapy in prostate cancer

Kallio Heini M L , Annala Matti , Brofeldt Anniina , Hieta Reija , Kivinummi Kati , Tammela Teuvo , Nykter Matti , Lilja Hans G , Bova G Steven , Visakorpi Tapio

Prostate cancer (PC) is the most common malignancy and third most common cause of cancer-related death among men in Europe. Although most PCs grow slowly, 20–25% of the patients believed to have organ-confined disease will experience biochemical recurrence already during 5-years of follow-up. The standard treatment against advanced PC is androgen deprivation (ADT). Unfortunately, androgen deprivation treatment eventually fails leading to the emergence of castration resist...

ea0042oc9 | (1) | Androgens2016

Chromatin relaxation is a feature of advanced prostate cancer

Urbanucci Alfonso , Barfeld Stefan , Kytola Ville , Vodak Daniel , Sjoblom Liisa , Tolonen Teemu , Minner Sarah , Burdelski Christoph , Kivinummi Kati K. , Kregel Steven , Takhar Mandeep , Alshalalfa Mohammed , Davicioni Elai , Erho Nicholas , Karnes R. Jeffrey , Ross Ashley E. , Schaeffer Edward M. , Vander Griend Donald J. , Knapp Stefan , Tammela Teuvo L.J. , Sauter Guido , Schlomm Thorsten , Nykter Matti , Visakorpi Tapio , Mills Ian G.

Epigenetic reprogramming including altered transcription factor binding and altered patterns of chromatin and DNA modifications are now accepted as the hallmark of aggressive cancers. We show that global changes in chromatin structure and chromatin accessibility in prostate tumour tissue can define castrate-resistant prostate cancer and be used to inform the discovery of gene-level classifiers for therapy. In addition, we show that the androgen receptor overexpression alone, w...